Review
Urology & Nephrology
Thi Oanh Bui, Van Tu Dao, Van Tai Nguyen, Jean-Paul Feugeas, Frederic Pamoukdjian, Guilhem Bousquet
Summary: Genetic tumor heterogeneity is a major cause of resistance in metastatic renal cell carcinoma patients. A meta-analysis of genomic data from 14,696 patients revealed a higher level of mutations in metastases compared to primary tumors, emphasizing the importance of biopsies on metastases in guiding treatment strategies.
Review
Biochemistry & Molecular Biology
Juan P. Rodrigo, Mario Sanchez-Canteli, Fernando Lopez, Gregory T. Wolf, Juan C. Hernandez-Prera, Michelle D. Williams, Stefan M. Willems, Alessandro Franchi, Andres Coca-Pelaz, Alfio Ferlito
Summary: Tumor-infiltrating lymphocytes (TIL) have been shown to be prognostically significant in Laryngeal Squamous Cell Carcinoma (LSCC), with high stromal TIL, CD8+ TIL, and CD3+/CD4+ TIL associated with better clinical outcomes. Evaluation of TIL in HE sections and assessment of CD3+, CD4+, and/or CD8+ TIL levels may serve as predictive markers for patient prognosis in LSCC.
Article
Biochemistry & Molecular Biology
Bin Zheng, Fang Xie, Fajuan Cheng, Jianwei Wang, Zhongshun Yao, Wei He, Zhihong Niu
Summary: This study comprehensively assessed the tumor microenvironment of kidney cancer, identified two immune-related hub genes - IGLL5 and IL2RA, and validated their clinical application value in ccRCC and pRCC. Drug response was also predicted based on selected genes, revealing novel drug candidates for RCC treatment.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Multidisciplinary Sciences
Kangsan Kim, Qinbo Zhou, Alana Christie, Christina Stevens, Yuanqing Ma, Oreoluwa Onabolu, Suneetha Chintalapati, Tiffani Mckenzie, Vanina Toffessi Tcheuyap, Layton Woolford, He Zhang, Nirmish Singla, Pravat Kumar Parida, Mauricio Marquez-Palencia, Ivan Pedrosa, Vitaly Margulis, Arthur Sagalowsky, Zhiqun Xie, Tao Wang, Steffen Durinck, Zora Modrusan, Somasekar Seshagiri, Payal Kapur, James Brugarolas, Srinivas Malladi
Summary: In this study, the authors explore the determinants of vascular invasion and metastasis in RCC patients with tumor thrombi (TT). They found that tumor thrombi associated with metastases are characterized by higher grade, mTOR activation, and a particular immune contexture. TT grade is a better predictor of metastasis than overall tumor grade.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Jing-min Zheng, Mei-fu Gan, Hong-yuan Yu, Lu-xia Ye, Qing-xin Yu, Yu-hui Xia, Han-xi Zhou, Jia-qian Bao, Yi-qing Guo
Summary: KDF1 has been identified as a key regulator of epidermal proliferation and differentiation, but its involvement in malignancy remains unknown. This study explored the role of KDF1 in clear cell renal cell carcinoma (ccRCC) through analyzing its expression levels and functions. The results suggest that KDF1 may act as a tumor suppressor in ccRCC by inhibiting proliferation and invasion of cancer cells.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Takashi Kuroe, Reiko Watanabe, Motohiro Kojima, Ryo Morisue, Masato Sugano, Takeshi Kuwata, Hitoshi Masuda, Shota Kusuhara, Nobuaki Matsubara, Shioto Oda, Tetsuo Ushiku, Genichiro Ishii
Summary: The study identified two patterns of tumor necrosis in renal cell carcinoma: dirty necrosis and ghost necrosis. Dirty necrosis was significantly associated with unfavorable clinicopathological factors, with the TN area and number of necrotic foci correlated with tumor size. This suggests that dirty necrosis may serve as an unfavorable prognostic indicator in surgically resected RCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Genetics & Heredity
Jie Ming, Chunyang Wang
Summary: This study identified m7G-related lncRNAs and constructed a 12 m7G-related lncRNA prognostic signature for clear cell renal cell carcinoma (ccRCC) using transcriptome data and clinical data from TCGA. The risk signature showed high accuracy and reliability in predicting overall survival (OS) of ccRCC patients. Additionally, functional enrichment analysis and immunological analysis were performed, providing insight into the biological pathways and immune characteristics of ccRCC.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Wei Zhang, Wenqiang Liu, Yiren Yang, Chengwu Xiao, Yutian Xiao, Xiaojie Tan, Qingyang Pang, Han Wu, Meimian Hua, Xiaolei Shi
Summary: By integrating transcriptomic landscape and urinary signature, a urine-based prognostic classifier consisting of VSIG4, TGFBI, and P4HB was developed to predict ccRCC prognosis and may facilitate ccRCC molecular subtyping and treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Changqing Mao, Weixin Xu, Weina Ma, Chun Wang, Zhaojiao Guo, Jun Yan
Summary: The meta-analysis revealed that low PNI is associated with shorter survival outcomes in patients with renal cell carcinoma, indicating that PNI could be used as an effective prognostic indicator in RCC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Liu-xun Chen, Shen-jie Zeng, Xv-dong Liu, Hai-bin Tang, Jia-wu Wang, Qing Jiang
Summary: This study characterizes the intercellular communications within the ccRCC microenvironment and shows their impact on prognosis and immunotherapy efficacy. It reveals a potential relationship between the VHL phenotype and the landscape of cell-cell communication. Moreover, these communication molecules also influence the development and infiltration of T cells and myeloid cells. Different clusters of intercellular communications have significant predictive value for prognosis and distinguish immunotherapy efficiency.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Medicine, General & Internal
Li Yuxuan, Li Junchao, Liu Wenya
Summary: This study conducted a meta-analysis to explore the impact of sarcopenia on the survival and recurrence outcome of renal cell carcinoma (RCC) patients. The results showed that sarcopenia can be used as an independent predictor of overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) in RCC patients.
Review
Biochemistry & Molecular Biology
Mingyang Li, Lei Li, Jianyi Zheng, Zeyu Li, Shijie Li, Kefeng Wang, Xiaonan Chen
Summary: Renal cell carcinoma (RCC) is a common type of kidney cancer with unremarkable symptoms in early stages and low sensitivity to radiotherapy and chemotherapy. Liquid biopsy, an emerging non-invasive test, can measure patient biomarkers for diagnosis, prognostic assessment, treatment monitoring, and response evaluation. With rapid development and iteration of extraction and analysis technologies, liquid biopsy has become a low cost, high efficiency, and high accuracy clinical detection method. In this review, we comprehensively discuss the components, clinical applications, limitations, and future prospects of liquid biopsy in the past 5 years.
Review
Oncology
Huaying Mao, Fan Yang
Summary: This meta-analysis study shows that the albumin-to-globulin ratio (AGR) is associated with the prognosis and clinicopathological characteristics of renal cell carcinoma (RCC). A low AGR is significantly correlated with worse overall survival and progression-free survival in RCC, as well as with female sex, advanced tumor stage, lymph node metastasis, tumor necrosis, and high tumor grade. Therefore, AGR has important prognostic and clinical implications in RCC.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
Tomas Blazek, Marek Petras, Lukas Knybel, Jakub Cvek, Renata Soumarova
Summary: This study suggests that PD-L1 expression on immune cells may serve as a new prognostic biomarker in patients with head and neck squamous cell carcinoma (HNSCC). However, further studies are warranted to verify this potential role due to the limited number of studies conducted to date.
Article
Oncology
Xinqiang Gan, Ruiji Liu, Hong Cheng, Weipu Mao, Ninghan Feng, Ming Chen
Summary: The study revealed that ASNS expression is significantly increased in ccRCC and is associated with advanced clinicopathological characteristics. ASNS may play a significant role in the development and immune cell infiltration of ccRCC and can serve as a valuable clinical prognostic biomarker.
FRONTIERS IN ONCOLOGY
(2022)